Pharmacological Approach to Improve the Outcome of Social Cognition Training

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST). The primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater improvements in a summary measure of social cognition than subjects treated with placebo over the course of SCST.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Greater Los Angeles Healthcare System
• Collaborator: National Alliance for Research in Schizophrenia and Affective Disorders
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition

• Stable on an antipsychotic medication

• No change in antipsychotic dose of >10% during the past 3 months

Exclusion Criteria:

• Unable to provide informed consent

• History of epilepsy

• Active medical conditions that would make the study unsafe

• History of serious head injury

• History of hyponatremia